The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma

Targeted Oncology

Volumn 10, Issue 1, 2015, Pages 15-26

  Read, Evan D ^a   Eu, Peter ^b   Little, Peter J ^a   Piva, Terrence J ^a  

^a RMIT UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

CD20; Lymphoma; NHL; Radioimmunotherapy; Rituximab; Targeted alpha therapy

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

HUMAN; LYMPHOMA, NON-HODGKIN; MOLECULARLY TARGETED THERAPY; PROCEDURES; RADIOIMMUNOTHERAPY;

ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; RADIOIMMUNOTHERAPY; RITUXIMAB;

EID: 84939877444     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0324-y     Document Type: Review

References (106)

1. Boffetta P (2011) Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol 22(Suppl 4):iv27–iv31. doi:10.1093/annonc/mdr167
2. Ho W, Shukla S, Mills L, Negrello T, Min H, Connell E, Ganner Bech A, Budd A, Chen C, Davis B, Goodwin M, Meere D, Short A, Tanevska B (2012) Cancer in Australia: an overview. Australian Institute of Health and. Welfare & Australasian Association of Cancer Registries, Canberra
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. (2014) National Cancer Institute. http://seer.cancer.gov/statfacts/html/nhl.html. Accessed January 15 2014
4. Jaffe ES (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program:523-531. doi: 10.1182/asheducation-2009.1.523
5. Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol 5(6):341–353. doi:10.1016/S1470-2045(04)01490-1
6. Leich E, Ott G, Rosenwald A (2011) Pathology, pathogenesis and molecular genetics of follicular NHL. Best Pract Res Clin Haematol 24(2):95–109. doi:10.1016/j.beha.2011.02.003
7. Nogai H, Dörken B, Lenz G (2011) Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 29(14):1803–1811. doi:10.1200/jco.2010.33.3252
8. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York
9. DeNardo GL (2005) Treatment of non-Hodgkin’s lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 35(3):202–211. doi:10.1053/j.semnuclmed.2005.02.006
10. Wilson WH, Gutierrez M, O’Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML (2002) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29(1, Supplement 2):41–47. doi:10.1053/sonc.2002.30151
11. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4):1259–1266
12. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23(6):1103–1108. doi:10.1200/jco.2005.12.052
13. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22(23):4711–4716. doi:10.1200/jco.2004.04.020
14. Lossos IS, Gascoyne RD (2011) Transformation of follicular lymphoma. Best Pract Res Clin Haematol 24(2):147–163. doi:10.1016/j.beha.2011.02.006
15. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135(2):973–979
16. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 121(5):1121–1132. doi:10.1083/jcb.121.5.1121
17. Juweid ME (2002) Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. J Nucl Med 43(11):1507–1529
18. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435–445
19. Rezvani AR, Maloney DG (2011) Rituximab resistance. Best Pract Res Clin Haematol 24(2):203–216. doi:10.1016/j.beha.2011.02.009
20. Bello C, Sotomayor EM (2007) Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematol Am Soc Hematol Educ Prog 2007(1):233–242. doi:10.1182/asheducation-2007.1.233
21. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22(47):7359–7368. doi:10.1038/sj.onc.1206939
22. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I (2000) Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 204(1):55–63. doi:10.1006/cimm.2000.1693
23. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48(12):673–683
24. Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS (2003) CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res 63(17):5480–5489
25. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99(3):1038–1043
26. van der Kolk LE, Evers LM, Omene C, Lens SM, Lederman S, van Lier RA, van Oers MH, Eldering E (2002) CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 16(9):1735–1744. doi:10.1038/sj.leu.2402559
27. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F (2000) Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37–41
28. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17(1):268
29. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23(9):1117–1125. doi:10.1038/nbt1135
30. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312(5995):643–646
31. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18(17):3135–3143
32. Roche (2013) Mabthera summary of product characteristics. http://www.roche-australia.com/fmfiles/re7229005/downloads/oncology/mabthera-pi.pdf. Accessed 16 January 2014
33. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825–2833
34. van Oers MH, Kersten MJ (2011) Treatment strategies in advanced stage follicular lymphoma. Best Pract Res Clin Haematol 24(2):187–201. doi:10.1016/j.beha.2011.03.003
35. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90(6):2188–2195
36. Hainsworth JD (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 29(1, Supplement 2):25–29. doi:10.1053/sonc.2002.30154
37. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17(4):1244
38. Hernandez MC, Knox SJ (2004) Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 59(5):1274–1287. doi:10.1016/j.ijrobp.2004.02.065
39. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463
40. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5):441–449. doi:10.1056/NEJMoa041511
41. 131I anti-B1 (anti-CD20) antibody. N Engl J Med 329(7):459–465. doi:10.1056/nejm199308123290703
42. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 44(3):465–474
43. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin’s lymphoma. Int J Oncol 15(5):1017–1025
44. Fuerst M (2013) Underprescribed Bexxar discontinued by GlaxoSmithKline. Oncology Times. http://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=800. Accessed January 17 2014
45. Boswell CA, Brechbiel MW (2007) Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 34(7):757–778. doi:10.1016/j.nucmedbio.2007.04.001
46. 90Y-ibritumomab tiusetan radioimmunotherapy is highly effective for relased or refractory indolent B-Cell non-Hodgkin’s lymphoma pre-treated with rituximab-containing chemotherapy: Japanese multicentre trial Phase II study. Blood 108 (Annual Meeting Abstract 2767)
47. Mulford DA, Scheinberg DA, Jurcic JG (2005) The promise of targeted {alpha}-particle therapy. J Nucl Med 46(Suppl 1):199S–204S
48. 131I-tositumomab in clinical practice. J Nucl Med 48(11):1767–1776. doi:10.2967/jnumed.107.043489
49. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 39(1–2):181–194
50. Zinzani PL, d’Amore F, Bombardieri E, Brammer C, Codina JG, Illidge T, Jurczak W, Linkesch W, Morschhauser F, Vandenberghe E, Van Hoof A (2008) Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice—report of a European workshop. Eur J Cancer 44(3):366–373. doi:10.1016/j.ejca.2007.12.008
51. 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med 50(11):1837–1843. doi:10.2967/jnumed.109.067587
52. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 18(6):1316–1323
53. 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy. Cancer Biother Radiopharm 24(1):103–110. doi:10.1089/cbr.2008.0538
54. 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117(1):45–52. doi:10.1182/blood-2010-02-269753
55. Leahy MF, Seymour JF, Hicks RJ, Turner JH (2006) Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 24(27):4418–4425. doi:10.1200/jco.2005.05.3470
56. 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 71(4):945–953. doi:10.1007/s00280-013-2087-z
57. 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience. Eur J Nucl Med Mol Imaging 32(10):1225–1233. doi:10.1007/s00259-005-1770-7
58. 177Lu-DOTA-anti-CD20 for radioimmunotherapy. J Radioanal Nucl Chem 287(1):199–209. doi:10.1007/s10967-010-0676-4
59. 177Lu-DOTA-rituximab: final results of a phase I/II study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J Nucl Med 54(7):1045–1052. doi:10.2967/jnumed.112.115170
60. 177Lu process. Appl Radiat Isot 53(3):421–425. doi:10.1016/S0969-8043(99)00284-5
61. 176Yb targets. Appl Radiat Isot 63(1):23–36. doi:10.1016/j.apradiso.2005.02.005
62. 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging 36(9):1443–1452. doi:10.1007/s00259-009-1120-2
63. 177Lu DOTA-anti-CD20: labeling and pre-clinical studies. Appl Radiat Isot 69(7):924–928. doi:10.1016/j.apradiso.2011.01.026
64. 177Lu-labeled rituximab for B-lymphoma treatment. Iran J Nucl Med 18 (14)
65. Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW (2007) Evaluation of CD20, CD22 and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res 67(12):5921–5928. doi:10.1158/0008-5472.can-07-0080
66. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25(9):1341–1351
67. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100(4):1233–1239
68. 211At-rituximab against non-Hodgkin’s lymphoma cells. Br J Cancer 83(10):1375–1379. doi:10.1054/bjoc.2000.1453
69. Vaidyanathan G, Zalutsky MR (2008) Astatine radiopharmaceuticals: prospects and problems. Curr Radiopharm 1(3):177
70. Sgouros G (2008) Alpha-particles for targeted therapy. Adv Drug Deliv Rev 60(12):1402–1406. doi:10.1016/j.addr.2008.04.007
71. 211At alpha-radioimmunotherapy. Book of Abstracts 4th Alpha-Immunotherapy Symposium
72. 213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Appl Radiat Isot 55(5):667–678. doi:10.1016/S0969-8043(01)00062-8
73. Chouin N, Bardies M (2011) Alpha-particle microdosimetry. Curr Radiopharm 4(3):266–280
74. Dahle J, Krogh C, Melhus KB, Borrebæk J, Larsen RH, Kvinnsland Y (2009) In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate thorium-227–DOTA–rituximab. Int J Radiat Oncol Biol Phys 75(3):886–895. doi:10.1016/j.ijrobp.2009.04.062
75. 213Bi anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 4(2):218–230
76. Miederer M, Scheinberg DA, McDevitt MR (2008) Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev 60(12):1371–1382. doi:10.1016/j.addr.2008.04.009
77. 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging 30(10):1357–1364. doi:10.1007/s00259-003-1228-8
78. Aurlien E, Kvinnsland Y, Larsen RH, Bruland OS (2002) Radiation doses to non-Hodgkin’s lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation. Int J Radiat Biol 78(2):133–142. doi:10.1080/09553000110094788
79. 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy. Nucl Med Biol 33(2):271–279. doi:10.1016/j.nucmedbio.2005.12.004
80. Vandenbulcke K, Thierens H, Offner F, Janssens A, de Gelder V, Bacher K, Philippe J, De Vos F, Dierckx R, Apostolidis C, Morgenstern A, Slegers G (2004) Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study. Nucl Med Commun 25(11):1131–1136
81. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot 50(5):895–904. doi:10.1016/S0969-8043(98)00151-1
82. 227Th-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm 22(3):431–437
83. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 57(6):841–847
84. Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA (2005) Renal tubulointerstitial changes after internal irradiation with α-particle-emitting actinium daughters. J Am Soc Nephrol 16(9):2677–2689. doi:10.1681/asn.2004110945
85. Boll RA, Malkemus D, Mirzadeh S (2005) Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot 62(5):667–679. doi:10.1016/j.apradiso.2004.12.003
86. Roy K, Lahiri S (2008) Production and separation of astatine radionuclides: some new addition to astatine chemistry. Appl Radiat Isot 66(5):571–576. doi:10.1016/j.apradiso.2007.12.005
87. Zalutsky MR, Vaidyanathan G (2000) Astatine-211 labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 6(14):1433–1455
88. 211At labelled antineoplastic antibodies. J Pharm Pharm Sci 10(2):277s–285s
89. Ning L, Jiannan J, Shangwu M, Hengliu C, Yanping Y (1998) Preparation and premilinary evaluation of astatine-211 labeled IgG via DTPA anhydride. J Radioanal Nucl Chem 227(1–2):187–190. doi:10.1007/BF02386459
90. Norseyev Y, Shmakova N (1995) Astatine-211: production, injection into monoclonal antibodies, radiobiologic effect, possible application to cancer treatment. Nukleonika 40(1):13–25
91. Zalutsky MR, Pruszynski M (2011) astatine-211: production and availability. Curr Radiopharm 4(3):177–185
92. Huclier-Markai S, Alliot C, Varmenot N, Cutler CS, Barbet J (2012) Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics. Curr Top Med Chem 12(23):2642–2654
93. 125I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts. J Label Compd Radiopharm 34(8):773–785. doi:10.1002/jlcr.2580340811
94. Scheinberg DA, McDevitt MR (2011) Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm 4(4):306–320
95. Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA, Kearsley J (2005) Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 4(12):1318–1324
96. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med 54(9):1597–1604. doi:10.2967/jnumed.112.111997
97. 213Bi synergizes with prednisolone and fludabarine in inducing apoptosis in b-cell in vitro. J Label Compd Radiopharm 46(S1):S99–S106. doi:10.1002/jlcr.765
98. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Back T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW (2010) Conventional and pretargeted radioimmunotherapy using Bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116(20):4231–4239. doi:10.1182/blood-2010-05-282327
99. 213Bi-labeled antibody constructs for clinical use. J Nucl Med 40(10):1722–1727
100. Ma D, McDevitt MR, Finn RD, Scheinberg DA (2001) Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals. Appl Radiat Isot 55(4):463–470. doi:10.1016/S0969-8043(01)00048-3
101. Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J (2000) Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 15(1):15–29
102. 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12(20):6250s–6257s. doi:10.1158/1078-0432.ccr-06-0841
103. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA (2001) Tumor therapy with targeted atomic nanogenerators. Science 294(5546):1537–1540. doi:10.1126/science.1064126
104. 206Bi in the normal rat. Radiat Res 63(3):443–454
105. Slikkerveer A, Wolff F (1989) Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp 4(5):303–323. doi:10.1007/BF03259915
106. Cohen EP, Robbins ME (2003) Radiation nephropathy. Semin Nephrol 23(5):486–499